Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A SANCAK
Combination Therapy With Pegylated Interferon Plus Ribavirin in the Treatment of Hepatitis C Virus-Related Thrombocytopenia
Current Therapeutic Research
Pharmacology
Related publications
Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Associated With Thyroid Dysfunction
Acta Hepatologica Japonica
Hepatology
Treatment Response and Tolerability of Pegylated Interferon-Α Plus Ribavirin Combination Therapy in Elderly Patients (≥ 65 Years) With Chronic Hepatitis C in Korea
Hepatitis Monthly
Hepatology
Infectious Diseases
Hepatitis C Virus Core Protein Substitutions Affect the Response to Pegylated-Interferon and Ribavirin Therapy
BMC Genomics
Biotechnology
Genetics
The Effect of Pegylated Interferon-Alpha2b and Ribavirin Combination Therapy for Chronic Hepatitis C Infection in Elderly Patients
BMC Research Notes
Biochemistry
Medicine
Genetics
Molecular Biology
Sudden-Onset Sarcoidosis With Severe Dyspnea Developing During Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C
Turkish Journal of Gastroenterology
Gastroenterology
Cost-Effectiveness of Hepatitis C Virus (HCV) Treatment With Telaprevir/Pegylated Interferon Alpha/Ribavirin Triple Therapy Versus Waiting for New Regimens in France
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Decrease in Regulatory T-Cell Function in Chronic Hepatitis C Patients Receiving Pegylated-Interferon Plus Ribavirin
International Journal of Infectious Diseases
Medicine
Infectious Diseases
Microbiology
Oxidative Stress and Antioxidant Defense in Patients With Chronic Hepatitis C Patients Before and After Pegylated Interferon Alfa-2b Plus Ribavirin Therapy
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Safety and Efficacy of Pegylated Interferon Alpha-2a and Ribavirin Combination in Treatment of Egyptian Patients With Chronic Hepatitis C Genotype-4
IOSR Journal of Pharmacy (IOSRPHR)
